Background: PCNSL is an aggressive primary brain tumor. Outcome and treatment options are poor for recurrent/refractory (r/r) disease. Response rates (ORR) range between 30-60% with a progression free survival (PFS) of 2-5 months. Ibrutinib has shown promising clinical response in some B-cell malignancies. This trial investigates Ibrutinib in patients with r/r PCNSL and SCNSL. Methods: Eligible patients had r/r PCNSL or SCNSL, age ? 18, ECOG ?
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with I.
Contact I., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack